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were administered 25mg, 25.4% administered 37.5 mg and 37.1%
administered 50 mg doses.
Clinical Global Impression-Severity (CGI-S) and Global Assess-
ment of Function (GAF) scores were available for 325 patients.
The mean9SD CGI-S score decreased significantly from 4.591.1
at baseline to 3.791.1 and 3.691.1 at 12- and 24-months,
respectively (pB0.001 versus baseline). At baseline the mean9
SD GAF score was 42.2914.6, increasing to 55.5916.0 and
58.9915.3 at 12- and 24-months, respectively (pB0.001 versus
baseline).
Hospitalisations decreased from 1.22 new hospitalisations per
year during the 12-months before long-acting risperidone initiation
to 0.8 and 0.69 after 12- and 24-months, respectively, of long-acting
risperidone treatment.
A reduction in benzodiazepine use was observed, with no
changes in antidepressant, mood-stabiliser or somatic medication
use. A reduction in anticholinergic use was also observed (p
0.018).
Conclusions: Previously reported early improvements in function,
symptom control and hospitalisation continued to 12- and 24-
months following initiation on long-acting risperidone treatment.
N-ACETYL CYSTEINE AS A GLUTATHIONE
PRECURSOR FOR SCHIZOPHRENIA: A DOUBLE-
BLIND, RANDOMIZED, PLACEBO-CONTROLLED
TRIAL
Michael Berk, Ashley Bush, David Copolov, Olivia Dean,
Kristy Lu, Paul Katz, Ian Schapkaitz, Murray Anderson-
Hunt, Fiona Judd, Michel Cuenod
Background: Antioxidant defences and brain glutathione levels are
decreased in schizophrenia, with unknown relevance for this
disorder. N-acetyl cysteine (NAC) is a safe, orally bioavailable
precursor of glutathione.
Aims and methods: In a randomized, double-blind, multicenter,
placebo-controlled study, we evaluated people with schizophrenia
who were treated with NAC (1g BID) as an add-on to their
antipsychotic medication over a 24 week period, followed by a 4
week washout. The primary outcomes were change in Clinical
Global Impression (CGI) Severity and Improvement scales, and
change on the Positive and Negative Symptoms Scale (PANSS)
over the study period. Secondary outcomes included general
functioning and extrapyramidal side effects rating scores.
Results: 140 participants were randomly assigned to treatment.
NAC treatment led to a significant improvement over the study
period in CGI-Severity (CGI-S, mean difference [NAC-placebo;
95% confidence intervals], 0.26 [0.08, 0.44], p0.004), and
CGI-Improvement (CGI-I, 0.22 [0.03, 0.41], p0.025)
scores compared to placebo treatment. NAC induced a significantly
greater improvement compared to placebo treatment on PANSS
Negative (1.83 [0.32, 3.33], p0.018), PANSS General (
2.79 [0.20, 5.38], p0.035) and PANSS Total (5.97 [1.51,
10.44], p0.009) scores at Week 24 when compared to baseline.
NAC treatment also produced a significant improvement in
akathisia. Effect sizes at endpoint were 0.43 on the CGI-S, 0.52
for the PANSS negative subscale, 0.57 for the PANSS total,
consistent with moderate effects.
Conclusion: The observation of moderate effect sizes in a relatively
refractory cohort indicates that NAC is an effective augmentation
strategy for chronic schizophrenia.
CLOZAPINE: A RETROSPECTIVE ANALYSIS ON
AGGRESSIVE BEHAVIOR IN A HIGH SECURE
HOSPITAL
Inti Qurashi, E. Silva
Background: Violent behavior is a significant problem in most
psychiatric hospital settings. There is evidence that Clozapine, an
atypical antipsychotic medication, effectively reduces violent and
aggressive behaviors regardless of the underlying psychiatric
diagnosis.
Aims: To determine an association between the use of clozapine
and incidence of aggression in a High Secure Forensic Hospital in
the United Kingdom using real-life outcome measures.
Method: We identified a retrospective cohort of 39 patients who i)
had consistently taken clozapine as antipsychotic monotherapy for
schizophrenia for 6 months ii) had a minimum 6 month inpatient
stay prior to starting Clozapine iii) had at least one aggressive
incident in the six months prior to Clozapine initiation.
Clinical notes and adverse incident databases were reviewed to
record aggressive incidents for the 12 month period both before and
after clozapine initiation.
Results: Of our sample of 39 patients: 23 (59%) showed a reduction
in incidents of all kinds. For 14 (36%) incidents stopped entirely.
The total of all incidents declined markedly. One outlier with
multiple incidents had started neuro-rehabilitation 16 weeks after
clozapine (and a significant reduction in incidents). When this
patient’s results were excluded the trends remained. Statistically
significant reductions (pB0.05; wilcoxon test) were achieved for
violent incidents and verbal aggression.
Conclusions: Clozapine is associated with clinically meaningful
reduction in aggression.
CLOZAPINE ASSOCIATED CARDIOTOXICITY:
FINDINGS FROM BARWON HEALTH
Joanna Fitzsimons, Tim Lambert, Seetal Dodd, Christos
Pantelis, Bill Kuluris, Tom Callaly, Michael Berk
Background: Clozapine has a unique efficacy profile that to date
has not been matched or enhanced by other second-generation
antipsychotics. However, the risk of life threatening adverse effects
associated with clozapine treatment remains. Myocarditis and
dilated cardiomyopathy are acknowledged adverse effects asso-
ciated with clozapine treatment and pose a serious risk to patients,
yet a dearth of investigation in this area remains.
Aims: The current study aims to investigate changes in cardiac
functioning, specifically left ventricular (LF) functioning, in
patients treated for the first time with clozapine.
Methods: Transthoracic echocardiograms were conducted on
seventy-four clozapine naı¨ve patients, prior to commencing cloza-
pine treatment (Time 1) and were repeated after 6 to 12 months
(Time 2), as part of routine cardiac monitoring. Patient psychiatric
and medication history were documented, as were full white blood
count and myocardial markers.
Results: Analyses of LV shortening, LV systolic functioning, LV
size and overall cardiac functioning revealed a non-significant trend
towards an increase in cardiac dysfunction from Time 1 to Time 2.
A significant decrease in LV shortening was seen when comparing a
group of clozapine-naı¨ve patients with a group of long-term treated
patients (pB0.001).
A282 AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2007) 41 (Suppl. 2)
A
us
t N
Z 
J P
sy
ch
ia
try
 D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
D
ea
ki
n 
U
ni
ve
rs
ity
 o
n 
11
/2
1/
11
Fo
r p
er
so
na
l u
se
 o
nl
y.
